European Society of Cardiology (ESC) Congress 2024

London, UK & Online 30 August 2024 - 02 September 2024

Ever considered interrupting the β-blocker in a stable post-MI patient? ABYSS suggests don’t

04 Oct 2024 by

In stable post-MI patients without a reduced EF who have been on long-term β-blockers, interrupting the β-blocker treatment instead of continuing it leads to more hospitalizations for CV reasons and does not improve QoL, as shown in the phase III ABYSS trial presented at ESC 2024

Ever considered interrupting the β-blocker in a stable post-MI patient? ABYSS suggests don’t

04 Oct 2024

The FINEART of finerenone: A new option for HFmrEF/HFpEF?

03 Oct 2024 by

Full results of the phase III FINEARTS-HF trial have shown that finerenone cuts the risk of worsening heart failure (HF) events and cardiovascular (CV) death in symptomatic HF with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF).

The FINEART of finerenone: A new option for HFmrEF/HFpEF?

03 Oct 2024

TAVI superior to surgery in women with aortic stenosis

01 Oct 2024 by

In women with severe symptomatic aortic stenosis (AS), transcatheter aortic valve implantation (TAVI) is superior to conventional surgery in terms of reducing death, stroke, and rehospitalization at 1 year, according to the RHEIA* trial presented at ESC 2024.

TAVI superior to surgery in women with aortic stenosis

01 Oct 2024

Pre-cath lab: To fast or not?

19 Sep 2024 by

The SCOFF* trial presented at ESC 2024 shows that fasting is not necessary prior to cardiac catheterization procedures requiring conscious sedation.

Pre-cath lab: To fast or not?

19 Sep 2024

Single, triple-combo pill hits BP target in two phase III trials

18 Sep 2024 by

GMRx2, a novel low-dose single pill containing three antihypertensive drugs – telmisartan, amlodipine, and indapamide – achieves all efficacy endpoints in two pivotal phase III trials presented at ESC 2024.

Single, triple-combo pill hits BP target in two phase III trials

18 Sep 2024

HELIOS-B shines on vutrisiran for ATTR-CM

16 Sep 2024 by

In the phase III HELIOS-B trial, vutrisiran reduced death and cardiovascular (CV) events in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM).

HELIOS-B shines on vutrisiran for ATTR-CM

16 Sep 2024

NOACs better than VKAs at preventing deaths, CVD in AF patients with or without impaired kidney

15 Sep 2024 by

For atrial fibrillation (AF) patients with normal or impaired renal function, use of nonvitamin K antagonist oral anticoagulants (NOACs) results in improved outcomes relative to vitamin K antagonist (VKA) therapy, suggests a study presented at ESC 2024.

NOACs better than VKAs at preventing deaths, CVD in AF patients with or without impaired kidney

15 Sep 2024

Diabetes, insulin use up risk of death, cardiac events in AF patients

14 Sep 2024 by

In patients with atrial fibrillation (AF), being diabetic contributes to an increased risk of all-cause death, cardiovascular disease (CVD), myocardial infarction (MI), major bleeding, and major adverse cardiovascular events (MACE), results of the GLORIA-AF study have shown.

Diabetes, insulin use up risk of death, cardiac events in AF patients

14 Sep 2024

Four-drug pill beats three separate meds in difficult-to-treat hypertension

07 Sep 2024 by

For individuals with difficult-to-treat hypertension who are struggling with three separate medications, a single pill that combines four blood pressure (BP)-lowering drugs may help with BP control, as shown in the phase III QUADRO trial.

Four-drug pill beats three separate meds in difficult-to-treat hypertension

07 Sep 2024

Tight potassium control to prevent AF after cardiac procedures may be unnecessary

06 Sep 2024 by

Relaxed control of potassium levels, with supplementation initiated only when levels drop to low, is as good as tight control in preventing atrial fibrillation (AF) after coronary bypass artery graft (CABG), as shown in the open-label TIGHT-K trial.

Tight potassium control to prevent AF after cardiac procedures may be unnecessary

06 Sep 2024